RGD PET/MRI in Sporadic Vestibular Schwannoma

• Status: Unknown status
• Trial end date: 2021-01-02
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this non-randomised, prospective study is to investigate the applicability and prognostic value of angiogenesis PET/MR with the radioligand 68Ga-NODAGA- E[c(RGDyK)]2 in patients with sporadic Vestibuarl Schwannomas.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rigshospitalet, Denmark

Criteria

Inclusion Criteria:

• Patients > 18 years with MRI verified sporadic vestibular schwannomas

• Patients > 18 år whom max has been in watchful waiting regime in 12 months and/or max. received 1 follow-up MRI scan.

• Must be able to read and understand the patient information in Danish and to give informed consent

Exclusion Criteria:

• Pregnancy

• Breast-feeding

• Weight more than the maximum weight limit for the PET/MR bed of the scanner (140 kg)

• History of allergic reaction attributable to compounds of similar chemical or biologic composition to 68Ga-NODAGA-E[c(RGDyK)]2

• Recent systemic treatment with steroids

• Hormone treatment incl. birth control pills.

• Claustrofobia

• Non-MRI compatible implants.